Show simple item record

2016-08-31Zeitschriftenartikel DOI: 10.1371/journal.pone.0161311
Impact and Lessons Learned from Mass Drug Administrations of Malaria Chemoprevention during the Ebola Outbreak in Monrovia, Liberia, 2014
dc.contributor.authorKühne, Anna
dc.contributor.authorTiffany, Amanda
dc.contributor.authorLasry, Estrella
dc.contributor.authorJanssens, Michel
dc.contributor.authorBesse, Clement
dc.contributor.authorOkonta, Chibuzo
dc.contributor.authorLarbi, Kwabena
dc.contributor.authorPah, Alfred C.
dc.contributor.authorDanis, Kostas
dc.contributor.authorPorten, Klaudia
dc.date.accessioned2018-05-07T19:19:38Z
dc.date.available2018-05-07T19:19:38Z
dc.date.created2016-09-13
dc.date.issued2016-08-31none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/re1fquBSzQWhk/PDF/27si8cS5I3DZw.pdf
dc.identifier.urihttp://edoc.rki.de/176904/2415
dc.description.abstractBackground: In October 2014, during the Ebola outbreak in Liberia healthcare services were limited while malaria transmission continued. Médecins Sans Frontières (MSF) implemented a mass drug administration (MDA) of malaria chemoprevention (CP) in Monrovia to reduce malaria-associated morbidity. In order to inform future interventions, we described the scale of the MDA, evaluated its acceptance and estimated the effectiveness. Methods: MSF carried out two rounds of MDA with artesunate/amodiaquine (ASAQ) targeting four neighbourhoods of Monrovia (October to December 2014). We systematically selected households in the distribution area and administered standardized questionnaires. We calculated incidence ratios (IR) of side effects using poisson regression and compared self-reported fever risk differences (RD) pre- and post-MDA using a z-test. Findings: In total, 1,259,699 courses of ASAQ-CP were distributed. All households surveyed (n = 222; 1233 household members) attended the MDA in round 1 (r1) and 96% in round 2 (r2) (212/222 households; 1,154 household members). 52% (643/1233) initiated ASAQ-CP in r1 and 22% (256/1154) in r2. Of those not initiating ASAQ-CP, 29% (172/590) saved it for later in r1, 47% (423/898) in r2. Experiencing side effects in r1 was not associated with ASAQ-CP initiation in r2 (IR 1.0, 95%CI 0.49–2.1). The incidence of self-reported fever decreased from 4.2% (52/1229) in the month prior to r1 to 1.5% (18/1229) after r1 (peng
dc.language.isoeng
dc.publisherRobert Koch-Institut, Infektionsepidemiologie
dc.subject.ddc610 Medizin
dc.titleImpact and Lessons Learned from Mass Drug Administrations of Malaria Chemoprevention during the Ebola Outbreak in Monrovia, Liberia, 2014
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-10046808
dc.identifier.doi10.1371/journal.pone.0161311
dc.identifier.doihttp://dx.doi.org/10.25646/2340
local.edoc.container-titlePLoS ONE
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-publisher-namePublic Library of Science
local.edoc.container-volumehttp://journ
local.edoc.container-issue2016
local.edoc.container-year11

Show simple item record